CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
MONTREAL and ANTWERP, Belgium March 3, 2026 /PRNewswire/ -- CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, announces the appointment of Ehab A. El-Gabry, MD , as Chief Medical Officer and Head of Companion Diagnostics. In this role, Dr. El-Gabry will provide medical and scientific leadership across CellCarta's biomarker programs and lead the company's global pathology organization, with a strategic focus on accelerating companion diagnostic (CDx) development and commercialization through digital pathology and AI-enabled image analysis. About CellCarta: CellCarta is a leading global CRO laboratory to the biopharmaceutical and biotechnology industries, partnering with translational medicine, biomarker, and clinical development teams to generate reliable, regulator-ready data. With fully owned and harmonized global laboratory operations, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Esperion to acquire Corstasis for cardiovascular franchise expansion [Yahoo! Finance]Yahoo! Finance
- Antibody-drug Conjugates (ADCs) in Oncology Market Competitive Landscape Report 2026: Comprehensive Insights About 200+ Companies and 220+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]Yahoo! Finance
- What Daiichi Sankyo Company (TSE:4568)'s ENHERTU EMA Filing and AI Oncology Push Mean For Shareholders [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&DBusiness Wire
- ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast CancerBusiness Wire